JAMILAH ALRAHIMI

Dr. JAMILAH ALRAHIMI

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Heart Views
Verified
Journal Article
Closed access
JAJAMILAH ALRAHIMI
JAMILAH ALRAHIMI
SAShukri AlSaif
Shukri AlSaif
MAMirvat Alasnag
Mirvat Alasnag
ZAZuhier Awan
Zuhier Awan
FAFawaz Almutairi
Fawaz Almutairi
ATAdel Tash
Adel Tash

23 November 2020 in Cureus
Verified
Journal Article
Open access
PDF file
WAWail Alkashkari
Wail Alkashkari
FAFaisal Al-Husayni
Faisal Al-Husayni
AAAhmed Almaqati
Ahmed Almaqati
JAJAMILAH ALRAHIMI
JAMILAH ALRAHIMI
SASaad Albugami
Saad Albugami
Tetralogy of Fallot (ToF) is considered the most frequent cyanotic congenital heart abnormality with a low adulthood survival rate if kept untreated. The majority of cases are symptomatic during infancy and mandate early treatment. Few instances of survival to asymptomatic middle-age patients have been reported, and they are decreasing due to early detection. We reported a case of a middle-aged man who was asymptomatic during his life and recently diagnosed with ToF. The patient underwent surgical repair with excellent outcomes. The case represents the possibility of diagnosing such cases in a relatively old patient despite medical development and advances.

19 March 2021 in Cureus
Verified
Journal Article
Open access
JAJAMILAH ALRAHIMI
JAMILAH ALRAHIMI
AAAbdulbari Aboud
Abdulbari Aboud
AAAbdullah S. AlQuhaibi
Abdullah S. AlQuhaibi
YAYazan Almaghrabi
Yazan Almaghrabi
YAYousef S. Alghamdi
Yousef S. Alghamdi
HMHani N. Mufti
Hani N. Mufti
Obesity can increase cardiac mass and affect cardiac performance independently from other risk factors. Several studies have identified an association in patients who already have comorbidities, however, few studies focused on obesity as an isolated risk factor. This study aimed to assess the associations between isolated obesity and heart morphological and functional characteristics. This was a cross-sectional study that recruited 114 patients referred for echocardiographic study in King Faisal Cardiac Center. Adult patients who had a body mass index (BMI) above 25 kg/m2 were included, while patients with comorbidities such as hypertension, diabetes mellitus, dyslipidemia, or those who use medications for chronic diseases were excluded from this study. Variables of interest that we collected were age, gender, weight, BMI, and those related to morphological and functional changes in the heart including left ventricular mass index (LVMI), LV end-diastolic volume, and left ventricular ejection fraction (LVEF). Most of the study participants (63.8%) were class II or class III obesity and about 80% were males. The mean ± SD of LVEF was 55.7% ± 2.8%, while the mean of the left ventricular mass index was 28.5±5.84. The mean of LV end-diastolic volume index (LVEDVI) was slightly higher among males than females (48.8±11.6 versus 46.4±11.7 ml/m2), however, this difference was not statistically significant (p-value= 0.395). There was no correlation between BMI and LVMI in females (R - 0.226, R2 0.05, P-value 0.37), while the LVMI was found to have a negative correlation between BMI and male gender that was significant (R - 0.292, R2 0.09, P-value 0.0052). It was found that there is no correlation between LVEF and BMI for males and females (male= R 0.093, R2 0.032, P-value 0.093; female= R 0.172, R2 0.029, P-value 0.434). With regards to the LVEDVI, there was a negative correlation between higher BMI and male gender that was significant (male= R - 0.396, R2 0.157, P-value 0.0001) while it was not significant in females (R -0.0298, R2 0.0009, P-value 0.893). We have found that cardiac function is not affected by isolated obesity. However, indexed cardiac parameters like LVM and LV end diastolic volume were negatively correlated with higher BMI and positively correlated with relative wall thickness (RWT) only in males. This negative correlation might be one of the triggers to the development of obesity-induced cardiomyopathy.

1 January 2026 in Saudi Medical Journal
Verified
Journal Article
Open access
PDF file
JAJAMILAH ALRAHIMI
JAMILAH ALRAHIMI
SSShukri M. Al Saif
Shukri M. Al Saif
LHLaith Hussain-Alkhateeb
Laith Hussain-Alkhateeb
AAAli M. Albarrati
Ali M. Albarrati
OAOwayed M. Alshammeri
Owayed M. Alshammeri
ATAdel A. Tash
Adel A. Tash
Objectives: To develop an evidence-based clinical guideline for the prevention and management of cardiovascular diseases (CVDs) in Saudi Arabia, tailored to local epidemiology and healthcare needs. Methods: A multidisciplinary task force comprising cardiologists, public health specialists, and epidemiologists from different healthcare sectors in Saudi Arabia developed the guideline. Evidence synthesis was based on a comprehensive literature review and adaptation of international guidelines, particularly the 2021 European Society of Cardiology recommendations, contextualized to the Saudi setting. Results: The guideline provides recommendations for both primary and secondary CVD prevention. Primary prevention emphasizes risk assessment incorporating genetic, lifestyle, and clinical factors, as well as lipid and glucose profiling. Lifestyle modifications, including dietary changes, smoking cessation, physical activity, weight management, and psychosocial support, are prioritized. Pharmacologic therapy targets lipid levels, blood pressure, and glycemic control, tailored to individual risk categories. For secondary prevention, strategies include post-event risk stratification, comorbidity management (diabetes, hypertension, chronic kidney disease), and optimization of pharmacologic therapy for coronary artery disease, heart failure, cerebrovascular disease, and peripheral artery disease. Lifestyle interventions, supervised cardiac rehabilitation, and routine follow-up for complication monitoring and treatment adjustment are integral components. Conclusion: This guideline presents an updated, evidence-based framework specifically designed for the Saudi population, underscoring prevention, lifestyle modification, and optimized pharmacologic management to address the rising burden of CVDs.

1 January 2024 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
JAJAMILAH ALRAHIMI
JAMILAH ALRAHIMI
FAFatima Ali Ahmed
Fatima Ali Ahmed
DADan Atar
Dan Atar
The aim of the current work is to present a thorough recapitulation of the emerging understanding of atherosclerotic cardiovascular disease and recommending avenues for future studies. Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, influenced by a complex interplay of genetic, environmental, and atherothrombotic factors. Atherosclerosis, a multifaceted and dynamic process, is at the core of many CVDs. Recent studies have shed light on the multilayered nature of atherosclerosis and cardiovascular risk, emphasizing the need for a nuanced understanding of these diseases across different populations and disease mechanisms. This review synthesizes findings from 6 pivotal studies, shedding light on the intricate mechanisms underlying atherosclerotic cardiovascular events, the evolving understanding of atherosclerosis, and the potential pathways to attempt implementation in clinical practice. Insights into atherothrombotic factors, the role of macrophages, and the implications of aortic enlargement and coronary artery calcification underscore the complexity of CVD pathogenesis and highlight the need for comprehensive strategies in diagnosis, treatment, and prevention.

5 June 2020 in Cureus
Verified
Journal Article
Open access
WAWail Alkashkari
Wail Alkashkari
SASaad Albugami
Saad Albugami
FAFaisal Al-Husayni
Faisal Al-Husayni
JAJAMILAH ALRAHIMI
JAMILAH ALRAHIMI
MAMohammed Althobaiti
Mohammed Althobaiti
In this report, we describe the case of a 13-year-old male who presented to our hospital after sustaining injuries from a motor vehicle accident (MVA). A full-body CT scan revealed multiple injuries, including subgaleal hematoma, hemorrhagic brain contusion, moderate-size aortic pseudoaneurysm with associated mediastinal hematoma, and multiple stable visceral organ lacerations. Additionally, there were numerous fractures, including in the right femur associated with large hematoma. The patient was deemed at high risk for systemic anticoagulation required for an urgent operative aortic repair. Available percutaneous endograft sizes were deemed too large for his descending aortic diameter, and the associated potential risk of vessel injury from the large sheath required to implant the endograft removed this option from consideration. The decision was made to use a balloon-expandable covered stent, which is routinely used to treat coarctation of the aorta (CoA) as a life-saving alternative. A BeGraft aortic stent (Bentley InnoMed, Hechingen, Germany) measuring 16x38 mm was successfully implanted percutaneously with complete exclusion of the pseudoaneurysm without any procedural complications.